Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Pozycja w akcjach #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Cena akcji
$70.50
Ostatnia synchronizacja: 2025-11-14
Kapitalizacja rynkowa
$7.33B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
116.32%
Kraj
US
Handel Metsera, Inc. (MTSR)

Kategoria

Historia stopy dywidendy dla Metsera, Inc. (MTSR)
Stopa dywidendy (TTM) dla Metsera, Inc. (symbol akcji: MTSR) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Metsera, Inc. (MTSR) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
Rok Stopa dywidendy Zmień
Za mało danych dla podanych dat.
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji